Definium Therapeutics, Inc.(DFTX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Pending next ranking run
This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
DFTX Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Definium Therapeutics, Inc. (DFTX), a Healthcare sector company. DFTX is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Definium Therapeutics, Inc. reports net income of $-77.1M, free cash flow of $-42.6M. Top institutional holders of DFTX by reported 13-F value include BlackRock,, DRIEHAUS CAPITAL MANAGEMENT, Avoro Capital Advisors, based on the most recent SEC filings. DFTX trades on the Nasdaq exchange and files with the SEC under CIK 1813814. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate DFTX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Definium Therapeutics, Inc. directly from SEC EDGAR.
Net Income
Q1 2026
$-77.1M
Free Cash Flow
Q1 2026
$-42.6M
D/E Ratio
Q1 2026
0.15
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Net Income
-69.1% YoYOperating Income
-60.0% YoYEPS (Diluted)
-33.8% YoYTotal Assets
+45.7% YoYTotal Debt
+85.7% YoYOp. Cash Flow
-66.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Net Income | $-183.8M -69.1% | $-108.7M -13.5% | $-95.7M -68.6% | $-56.8M +39.0% | $-93.0M -174.1% | $-33.9M |
| Operating Income | $-166.3M -60.0% | $-103.9M -10.7% | $-93.9M -41.5% | $-66.3M +29.3% | $-93.9M -184.1% | $-33.0M |
| EPS (Diluted) | $-2.06 -33.8% | $-1.54 +36.9% | $-2.44 -32.6% | $-1.84 +45.9% | $-3.40 | — |
| Total Assets | $440.1M +45.7% | $302.2M +142.6% | $124.5M -26.7% | $170.0M +3.7% | $164.0M +101.2% | $81.5M |
| Total Debt | $40.6M +85.7% | $21.9M +54.7% | $14.1M | — | — | — |
| Operating Cash Flow | $-131.6M -66.3% | $-79.1M -22.9% | $-64.4M -28.4% | $-50.1M -9.4% | $-45.8M -94.2% | $-23.6M |
Get alerted when DFTX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Definium Therapeutics, Inc. including:
Top Institutional Holders of DFTX
BlackRock, Inc.
$160.3M8,480,230 shDRIEHAUS CAPITAL MANAGEMENT LLC
$111.7M5,911,889 shAvoro Capital Advisors LLC
$94.5M5,000,000 shDeep Track Capital, LP
$56.7M3,000,000 shGEODE CAPITAL MANAGEMENT, LLC
$47.2M2,495,399 shSTATE STREET CORP
$46.7M2,471,873 shOctagon Capital Advisors LP
$46.1M2,440,000 shCommodore Capital LP
$37.8M2,000,000 shFMR LLC
$34.2M1,809,610 shTrails Edge Capital Partners, LP
$32.9M1,738,110 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $160.3M | 8,480,230 |
| DRIEHAUS CAPITAL MANAGEMENT LLC | $111.7M | 5,911,889 |
| Avoro Capital Advisors LLC | $94.5M | 5,000,000 |
| Deep Track Capital, LP | $56.7M | 3,000,000 |
| GEODE CAPITAL MANAGEMENT, LLC | $47.2M | 2,495,399 |
| STATE STREET CORP | $46.7M | 2,471,873 |
| Octagon Capital Advisors LP | $46.1M | 2,440,000 |
| Commodore Capital LP | $37.8M | 2,000,000 |
| FMR LLC | $34.2M | 1,809,610 |
| Trails Edge Capital Partners, LP | $32.9M | 1,738,110 |
More Healthcare Companies
View all Healthcare →Put DFTX on your watchlist
Track score changes the day Definium Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is DFTX a good stock to buy?
13F Pro's AI-powered analysis of Definium Therapeutics, Inc. (DFTX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for DFTX are available on the DFTX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own DFTX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling DFTX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Definium Therapeutics, Inc.'s investment landscape.